Evaxion biotech opens new office and laboratories to support future growth

Copenhagen, denmark, feb. 16, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the opening of its new corporate headquarters and research laboratory facility located in the dtu science park in hoersholm near copenhagen, denmark.
EVAX Ratings Summary
EVAX Quant Ranking